Actinogen Medical (ACW) AI Stock Analysis

• Market Cap: $66.72M
• Dividend Yield: N/A
• Average Volume (3M): 12.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: N/A
• EPS Growth: 49.25%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 3,177,147,200
• 10 Day Avg. Volume: 3,891,138
• 30 Day Avg. Volume: 12,465,701
• PEG Ratio: -0.88
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The company's strong revenue growth is overshadowed by ongoing profitability and cash flow challenges, leading to a cautious outlook. Technically, the stock shows a bearish trend without significant oversold conditions, and valuation metrics reflect typical biotech sector hurdles.

Actinogen Medical Business Overview & Revenue Model

Company Description

Actinogen Medical Limited (ACW) is an Australian biotechnology company focused on the development of innovative treatments for cognitive impairment associated with neurological diseases, including Alzheimer’s disease. The company is primarily engaged in the research and development of Xanamem, a novel drug designed to inhibit the production of cortisol in the brain, which is believed to contribute to cognitive decline in neurodegenerative conditions.

How the Company Makes Money

Actinogen Medical Limited generates revenue through the development and potential commercialization of its flagship product, Xanamem. The company primarily invests in clinical trials and research activities to advance Xanamem through the regulatory approval process. Revenue is expected to be derived from licensing agreements, strategic partnerships, and potential sales of Xanamem upon successful approval and market entry. Actinogen may also engage in collaborations with larger pharmaceutical companies to co-develop or market Xanamem, leveraging these partnerships to enhance its financial position and market access.

Actinogen Medical Financial Statement Overview

Summary

Actinogen Medical Limited demonstrates strong revenue growth but struggles with profitability and cash flow management, typical of the biotechnology industry where heavy R&D spending is prevalent. While the balance sheet reflects financial stability through low leverage and high equity, the negative cash flow and operating losses present a challenge for sustainable growth.

Income Statement

The company shows a consistent increase in total revenue over the years, with a revenue growth rate of 103.2% from 2023 to 2024. Despite this growth, the company has been operating at a loss, evidenced by negative net income and EBIT margins. Gross profit margin remains strong as the cost of goods sold is negligible, but the high operating expenses lead to negative EBIT and net profit margins.

Balance Sheet

Stockholders' equity has increased over the years, indicating capital growth. The debt-to-equity ratio is very low, suggesting that the company is not heavily reliant on debt. However, the consistent negative net income impacts the return on equity negatively. The equity ratio is strong, highlighting financial stability with significant equity compared to total assets.

Cash Flow

The company has a negative operating cash flow, which has increased in magnitude, indicating higher cash burn. Though the company has managed to raise financing cash flow to cover its cash needs, free cash flow remains negative. The operating cash flow to net income ratio is concerning, reflecting inefficiencies in converting revenue to cash.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	9.02M	9.93M	4.89M	3.64M	1.98M	3.52M
Gross Profit	9.02M	9.93M	4.48M	3.24M	1.60M	3.10M
EBITDA	-9.64M	-12.92M	-15.22M	-12.72M	-5.35M	-8.20M
Net Income	-9.66M	-13.04M	-10.75M	-9.50M	-3.92M	-5.33M
Balance Sheet
Total Assets	25.43M	21.31M	15.21M	23.31M	18.38M	11.94M
Cash, Cash Equivalents and Short-Term Investments	22.87M	9.45M	8.46M	16.37M	13.42M	5.04M
Total Debt	289.64K	319.07K	86.93K	165.27K	236.44K	389.87K
Total Liabilities	1.46M	1.62M	1.80M	1.57M	920.32K	1.05M
Stockholders Equity	23.97M	19.70M	13.41M	21.74M	17.46M	10.89M
Cash Flow
Free Cash Flow	-8.73M	-16.96M	-8.73M	-9.52M	-1.73M	-2.88M
Operating Cash Flow	-8.72M	-16.95M	-8.70M	-9.52M	-1.72M	-2.86M
Investing Cash Flow	-9.03K	-8.16K	-36.60K	-2.94K	-6.19K	-22.76K
Financing Cash Flow	20.12M	17.95M	824.62K	12.42M	10.11M	282.26K

Actinogen Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.67 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACW.

Actinogen Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	70 Outperform	AU$117.46M	12.11	45.86%	2.46%	71.65%	152.89%
PTX	56 Neutral	AU$35.43M	―	-36.95%	―	―	11.11%
Sector *	48 Neutral	AU$2.44B	3.89	-64.25%	2.90%	35.15%	13.63%
ACW	46 Neutral	$66.72M	―	-55.44%	―	―	49.25%
ATH	45 Neutral	$91.27M	―	-154.88%	―	―	20.00%
ALA	40 Underperform	AU$118.53M	―	-85.35%	―	315.11%	51.16%
RAD	34 Underperform	AU$54.39M	―	-108.26%	―	―	53.41%

Actinogen Medical Corporate Events

BVF Partners Ceases Substantial Holding in Actinogen Medical

Actinogen Medical Limited has announced that BVF Partners L.P., along with its affiliates, has ceased to be a substantial holder in the company. This development follows a series of on-market sales of fully paid ordinary shares by BVF Partners and its associates, which took place between April 22 and May 19, 2025. The divestment of shares by BVF Partners may impact Actinogen Medical’s shareholder composition and could influence market perceptions of the company’s stock.

Actinogen’s Xanamem Shows Promise in Depression Treatment

Actinogen Medical announced positive results from a Phase 2 trial of its drug Xanamem, presented at the American Psychiatric Association’s 2025 meeting. The trial demonstrated that a 10 mg dose of Xanamem significantly improves symptoms of moderate Major Depressive Disorder, validating its mechanism of controlling brain cortisol levels. These findings not only highlight Xanamem’s potential as an effective antidepressant with a unique mechanism of action but also support its use in ongoing trials for Alzheimer’s Disease. The promising safety profile and durability of Xanamem’s benefits position it as a competitive candidate in the antidepressant market, potentially benefiting patients with Alzheimer’s who also suffer from depression.

Actinogen Medical Advances Alzheimer’s Treatment with Xanamem

Actinogen Medical announced a panel discussion featuring key company figures and experts to discuss advancements in Alzheimer’s treatments and the commercialization of Xanamem, their novel oral medication. The company is actively preparing for commercialization by designing pivotal trials, developing thought leaders, and refining communication strategies, which are crucial for maximizing future partnerships and addressing the significant unmet medical need for effective Alzheimer’s therapies.

Actinogen Medical Advances Alzheimer’s and Depression Trials with Regulatory and Manufacturing Milestones

Actinogen Medical has made significant progress in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, with accelerated patient screening and enrollment across multiple sites in the US and Australia. The company also achieved a successful regulatory meeting with the FDA regarding major depressive disorder, marking a major accomplishment that could enhance future partnerships and funding opportunities. Additionally, the World Health Organization granted a unique name to Xanamem, recognizing its novel mechanism of action, and the company continues to advance its manufacturing and strategic planning efforts.

Actinogen Medical Prepares for Xanamem Commercialization with Upcoming Forum

Actinogen Medical announced an upcoming Clinical Trials Science Forum to discuss advancements in Alzheimer’s treatments and the commercialization of Xanamem, their novel oral medication. The forum will highlight the company’s strategic planning for commercialization, including trial designs and stakeholder engagement, which are crucial for maximizing future partnerships and addressing the unmet need for effective Alzheimer’s therapies.

Actinogen Medical Sees Change in Substantial Holder’s Voting Power

Actinogen Medical Limited has seen a change in the interests of its substantial holder, BVF Partners L.P., which has reduced its voting power from 7.29% to 6.24% through a series of on-market sales of fully paid ordinary shares. This change in holdings may impact Actinogen’s market position and shareholder dynamics, as BVF Partners L.P. adjusts its investment strategy in the company.

Actinogen Medical Advances Alzheimer’s Research with Promising Xanamem Trial

Actinogen Medical announced that its Chief Medical Officer, Dr. Dana Hilt, presented an academic poster at the International Conference on Alzheimer’s & Parkinson’s Diseases. The poster highlighted the benefits of Xanamem treatment in patients with elevated blood pTau181, a biomarker for Alzheimer’s Disease, and informed the design of a new phase 2b/3 trial. This trial, currently recruiting in Australia and the USA, aims to evaluate the efficacy of Xanamem in slowing Alzheimer’s progression. Interim results are expected in late 2025, with final results anticipated in 2026. This development positions Actinogen as a key player in the Alzheimer’s treatment landscape, potentially impacting stakeholders by advancing therapeutic options for this debilitating condition.

Actinogen Advances Xanamem Development with FDA Meeting Success

Actinogen Medical announced the successful completion of a Type C meeting with the FDA regarding its major depressive disorder (MDD) program, reaching a consensus on the necessary clinical and nonclinical studies for future marketing approval of Xanamem. This development is a significant milestone for the company, enhancing its position in discussions with potential partners and supporting its ongoing efforts in clinical trials for Alzheimer’s and depression.